Prescribing guide
Imaavy (nipocalimab-aahu)Loading and maintenance dosing, infusion monitoring and prior authorization criteria for gMGFor prescribers and their offices treating generalized myasthenia gravis: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS. Prior authorization, age-appropriate vaccines before initiation, a site of care (office, infusion center or home), and no active infection on each dose day.
Example PA threshold
FEP example: age 12 or older, anti-AChR or anti-MuSK positive, MGFA II to IV, MG-ADL 6 or higher or QMG above 9, one failed AChE inhibitor or immunosuppressant.
Monitoring
Observe during and 30 minutes after each infusion; infection check before each dose; vaccines reviewed before initiation; no scheduled labs (lipids rose in Study 1, peaking at week 4).
Support line
IMAAVY withMe, Nurse Navigator 888-750-8733 (Monday to Friday 8 AM to 11 PM ET); Case Managers and savings 844-494-8463 (8 AM to 8 PM ET); as little as $0 per infusion for eligible commercial plans; Access Program for delays over 5 business days.
Give your patient their plan
A one-page handout for starting Imaavy, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/imaavyBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Enroll in IMAAVY withMe | Fax the Patient Enrollment Form to 877-332-1228 with a copy of the front and back of the insurance cards. Prescriber help line 844-4withMe (844-494-8463), Monday to Friday, 8 AM to 8 PM ET. | Enrollment form |
| Write the prescription on the form | Patient weight in kg, ICD-10 G70.00 or G70.01, initial 30mg/kg over at least 30 minutes, maintenance 15mg/kg over at least 15 minutes every 2 weeks, refills, and a ship-to infusion site if not the prescriber's office (no PO boxes). | Enrollment form |
| Routing | The form authorizes a benefits investigation and transmittal to a commercial pharmacy per the health plan, or to a no-cost dispensing pharmacy (Access Therapy Center is J&J's affiliated noncommercial pharmacy) under the Access Program or the J&J Patient Assistance Program. | Enrollment form |
| Calculate the dose | By current weight. 300mg/1.62mL and 1,200mg/6.5mL single-dose vials (185mg/mL), 1 per carton (NDC 57894-800-01, 57894-801-01). Dilute to 250mL at 40kg or more, 100mL under 40kg; use within 12 hours of preparation or removal from refrigeration, including infusion time. | FDA label |
| Billing codes | Permanent J-code J9256 (injection, nipocalimab-aahu, 3mg) effective January 1, 2026. Administration CPT codes listed: 96365 and 96413; payer policies vary. J&J notes an infusion of 15 minutes or less is an IV push. | IMAAVY HCP access page |
| Access Program, if coverage stalls | Commercially insured patients 12 or older with biologics coverage: no-cost drug for up to 3 years or until covered, after a non-covered response, a denial, or a delay of more than 5 business days after PA submission. Drug only, not administration. | Access Program terms |
| Access Program obligations | Submit a letter of medical necessity to the medical benefit payer within 30 days of the first infusion. Not eligible if the denial was for missing PA information or with government coverage. Up to 60 days to resubmit or appeal once told of commercial coverage. | Access Program terms |
| Savings Program | Commercial only, age 12 or older: medicine support to $0 per infusion with an annual maximum, plus administration and monitoring support capped at $7,000 a year. Rebates by EOB within 365 days of service. Excludes Medicare, Medicaid, TRICARE, DoD, VA and SaveOnSP plans. | Savings Program terms |
| State exclusions | Treatment Administration Cost Support is not valid for residents of Massachusetts, Minnesota or Rhode Island. Medicine Cost Support still applies. | Savings Program terms |
Prior authorization criteria and what to document
One public policy as the example: Blue Cross Blue Shield Federal Employee Program, July 1, 2026. Approval six months at first, then 12 months at a time if MG-ADL or QMG fell by 2 points or more, with no unacceptable side effects. This policy was approved on June 11, 2026, before the label added warm autoimmune hemolytic anemia in August 2026. It cites the April 2025 label, but the gMG dose and antibody rule have not changed since then. Its September 2025 review dropped a requirement to have tried 2 immunosuppressants first. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | Generalized myasthenia gravis, age 12 or older | Diagnosis in the note | FEP Blue policy |
| Serology | Autoantibodies against AChR or MuSK | Antibody result with date | FEP Blue policy |
| Severity | MGFA clinical class II to IV | Class recorded in the note | FEP Blue policy |
| Baseline score | MG-ADL total 6 or more, or QMG total above 9 | Dated score sheet | FEP Blue policy |
| Prior therapy | Inadequate response, intolerance or contraindication to one of: AChE inhibitor, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide | Agent, dose, dates and outcome | FEP Blue policy |
| Vaccines | Not given concurrently with live or live-attenuated vaccines | Vaccine history and plan | FEP Blue policy |
| Renewal | MG-ADL or QMG down 2 points or more from baseline and no unacceptable toxicity; first approval 6 months, renewals 12 months | Current score against baseline | FEP Blue policy |
Imaavy dosing and titration
| When | Label | Source |
|---|---|---|
| Initial dose | 30mg/kg IV once, over at least 30 minutes. Administer only by IV infusion after dilution. | FDA label |
| Maintenance | 15mg/kg IV over at least 15 minutes, starting 2 weeks after the initial dose and every 2 weeks thereafter. No cycles or planned breaks. | FDA label |
| Administration set | 0.2 micron or smaller in-line or add-on polyethersulfone or polysulfone filter; do not infuse in the same line with other agents. Slow or stop at the clinician's discretion if a reaction occurs. | FDA label |
| Missed dose | Administer as soon as possible, then resume dosing, maintaining the treatment interval (wording revised August 2026). | FDA label |
| Pediatric | Established for 12 and older; Study 2 (24 weeks, 7 AChR-positive patients aged 12 to 16) showed steady-state concentrations within the adult range. | FDA label |
| Renal and hepatic | No dose adjustment in renal impairment (eGFR 22 to 204 in population PK) or hepatic impairment. | FDA label |
| Other indication | wAIHA (added August 2026) uses 30mg/kg every 4 weeks; not covered on this page. | FDA letter |
Monitoring the Imaavy label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Each infusion | Hypersensitivity: angioedema, anaphylaxis, rash, urticaria, eczema | Observe during and 30 minutes after. Study 1 reactions from 1 hour to 2 weeks after dosing; 16% in Study 1 plus extension; 1 discontinuation for urticaria | FDA label |
| Each infusion | Infusion-related reactions: headache, influenza-like illness, rash, nausea, fatigue, dizziness, chills, erythema | Severe: stop and treat, weigh readministration. Mild to moderate: rechallenge with close observation, slower rate and premedication. 11% in Study 1 plus extension | FDA label |
| Before each dose | Active infection | Delay until resolved; if serious, treat and consider withholding. Respiratory 18% against 13%, UTI 6% against 3%, herpes 6% against 2%; serious infections 7% in Study 1 plus extension | FDA label |
| Ongoing | Latent viral reactivation | Herpes zoster risk; 2 serious EBV-related events in the extension, 1 fatal. Hepatitis-positive patients were excluded from Study 1 | FDA label |
| Before initiation | Vaccination status | Evaluate age-appropriate vaccines per immunization guidelines; live vaccines not recommended during treatment | FDA label |
| Weeks 4 to 24 | Lipids | Total cholesterol 240mg/dL or more in 24% and LDL 160mg/dL or more in 11% in Study 1; peak at week 4, mean increases of 14 and 7mg/dL by week 24. No monitoring schedule in the label | FDA label |
| Immunogenicity | Anti-drug antibodies | 48% (49/102) in gMG trials, 38.8% of those neutralizing; no clinically relevant effect on PK, PD, safety or efficacy identified | FDA label |
Imaavy drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Monitor closely | FcRn-binding agents: immunoglobulin products, monoclonal antibodies, antibody derivatives with a human IgG Fc domain; exposure and effect may fall. If long-term concomitant use is essential, consider discontinuing Imaavy | FDA label |
| CYP450 | Not metabolized by CYP450; CYP-mediated interactions unlikely | FDA label |
| Live vaccines | Not recommended during treatment; for infants exposed in utero, weigh risks and benefits before live vaccines | FDA label |
| Pregnancy | Limited human data; placental ischemia with fetal loss in monkeys at both doses tested; infant passive immunity may be reduced 6 months or more. Pregnancy safety study 1-800-526-7736 | FDA label |
| Lactation | Excreted in colostrum and breast milk (13 women); insufficient data on the breastfed infant | FDA label |
| Contraindicated | History of serious hypersensitivity to nipocalimab-aahu or excipients, including anaphylaxis and angioedema | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe FEP policy below asks for an AChR or MuSK antibody result, a symptom score and one earlier treatment that did not work. The neurologist's records usually answer what the plan is asking for.
- Commercial coverage delayed or deniedThe IMAAVY withMe Access Program may supply Imaavy at no cost for up to 3 years, or until the plan covers it. The prescriber must send a letter of medical necessity within 30 days of your first infusion.
- Denied because the form was incompleteThe Access Program does not cover a denial caused by missing information on the prior authorization or coverage form. Its terms list this as an exclusion, so a complete request matters.
- A copay you cannot payCommercial insurance: the IMAAVY withMe Savings Program, as little as $0 per infusion, with a yearly maximum. Medicare, Medicaid, TRICARE, VA and other government coverage are excluded. Our help paying page lists charity funds that may cover what remains.
- Your plan uses SaveOnSPThe Savings Program terms exclude patients whose plan partners with SaveOnSP, and may cut the maximum for other accumulator or maximizer plans. Call 844-494-8463 to talk through your options.
- You live in Massachusetts, Minnesota or Rhode IslandThe Savings Program's help with infusion administration and monitoring costs is not valid in these 3 states. Its help with the medicine itself still applies, so the clinic fee may fall on you.
- No insurance, or coverage that falls shortThe Johnson & Johnson Patient Assistance Program may provide Imaavy at no cost for up to 1 year if you meet its income rules. Call 844-494-8463 or see PatientAssistanceInfo.com/IMM.
IMAAVY withMe
- A dedicated Nurse Navigator, a registered nurse who calls within 1 to 2 business days of sign-up, with support in more than 100 languages. The enrollment form offers this to patients 18 and older and to caregivers of younger patients
- The IMAAVY withMe Savings Program for commercial insurance, as little as $0 per infusion, with a yearly maximum and a separate $7,000 yearly cap on administration and monitoring costs
- Savings help is not open to Medicare, Medicaid, TRICARE, Department of Defense or VA patients, under the program's terms
- The IMAAVY withMe Access Program, Imaavy at no cost for up to 3 years when commercial coverage is delayed more than 5 business days or denied
- The Johnson & Johnson Patient Assistance Program, no-cost medicine for up to 1 year for people who meet its income rules
- A Welcome Kit for infusion days, a Patient Portal and an Infusion Center Finder. Savings and Case Manager questions go to 844-494-8463, Monday to Friday, 8 AM to 8 PM Eastern
Questions prescribers' offices ask about Imaavy
What is the Imaavy dose for generalized myasthenia gravis?
30mg/kg IV once over at least 30 minutes, then 15mg/kg IV over at least 15 minutes starting 2 weeks later and every 2 weeks thereafter, per the August 2026 label. Dilute in 0.9% sodium chloride to 250mL (100mL if under 40kg) and infuse through a 0.2 micron filter. There are no treatment cycles or planned breaks.
Who is Imaavy indicated for in gMG?
Adult and pediatric patients 12 years and older who are anti-AChR or anti-MuSK antibody positive, per the August 2026 label, unchanged since the April 2025 approval. Seronegative gMG is not in the indication. Study 1 enrolled 88% AChR positive and 10% MuSK positive patients in the primary efficacy population.
Are vaccines or lab tests required before Imaavy?
No REMS, no required vaccine series and no scheduled lab in the August 2026 label. It says to evaluate age-appropriate vaccines per immunization guidelines before initiation, not before each dose, and that live vaccines are not recommended during treatment. Delay any dose during active infection.
What monitoring does Imaavy need?
Observe during and for 30 minutes after each infusion, per the August 2026 label. Hypersensitivity in Study 1 occurred from 1 hour to 2 weeks after dosing, and infusion-related reactions from 1 hour to 2 days. Watch for infection, including herpes zoster reactivation; the label reports 2 serious EBV events in the extension, 1 fatal.
What do insurers ask for to approve Imaavy?
The FEP policy shown here, effective July 1, 2026 and written before the August 2026 label, asks for age 12 or older, AChR or MuSK antibodies, MGFA class II to IV, MG-ADL of 6 or more or QMG above 9, one failed conventional agent and no concurrent live vaccines. It approves 6 months, then 12 months on a 2-point MG-ADL or QMG improvement without unacceptable toxicity.
Free email alert
Get an email when the Imaavy label changes
One email the day the FDA revises the Imaavy prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Imaavy only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- IMAAVY (nipocalimab-aahu) injection, for intravenous use, prescribing information and Patient Information, revised August 2026, Janssen Biotech, via DailyMed, 2026-08-21.
- IMAAVY (nipocalimab-aahu) injection, for intravenous use, prescribing information, revised 4/2025, FDA, Drugs@FDA, 2025-04-30.
- IMAAVY™ Costs & Savings Support | IMAAVY (nipocalimab-aahu), Johnson & Johnson, 2026-11-07.
- IMAAVY withMe - Commercial or Private Insurance | J&J withMe, Johnson & Johnson, 2026-10-07.
- IMAAVY withMe Savings Program for eligible patients using commercial insurance, with Savings Program Requirements, Johnson & Johnson, 2025-11-21.
- IMAAVY withMe Access Program, Program Description and Program Requirements, Johnson & Johnson, 2025-04-01.
- IMAAVY withMe Patient Enrollment Form (UPDATE 08.26), Johnson & Johnson, 2026-08-25.
- Access & Support for Your Patients | IMAAVY™ (nipocalimab-aahu), Johnson & Johnson, 2026-11-07.
- Pharmacy Policy 5.85.066, Imaavy (nipocalimab-aahu), Blue Cross Blue Shield Federal Employee Program, 2026-07-01.
- BLA 761430/S-002 supplement approval letter, warm autoimmune hemolytic anemia, FDA, 2026-08-24.
- BLA 761430 approval letter, Imaavy (nipocalimab-aahu) for generalized myasthenia gravis, FDA, 2025-04-29.
A reference drawn from the August 21, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 7, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.